Interview School

All segments

Segment 7Hot TopicsWith Hope Clarke

0% complete0 of 36 done

1How to answer any hot topic

2The resident doctors' strikes

3Physician associates and the Leng review

4Letby and the Thirlwall Inquiry

5Martha's Rule

6Maternity failures and infected blood

7Weight-loss jabs and obesity

8Smoking, vaping and prevention

9Vaccines, measles and the next pandemic

10Young people's mental health

11Health inequalities

12Climate, AMR and global health

0% complete

ReadingLesson 7 of 12

Weight-loss jabs and obesity

What this lesson covers

What the drugs do and what trials show
The NHS rollout, dated
Private jabs, prices and fakes
The arguments, and a line to hold
How this comes up on the day

The words to use

GLP-1 medicine: A drug that mimics a natural hormone released after eating, helping people feel fuller. Semaglutide (Wegovy) is one; tirzepatide (Mounjaro) also acts on a second hormone.
Funding variation: A NICE arrangement letting the NHS bring in an approved drug in phases, because too many people qualify to treat at once.
Major cardiovascular events: A combined trial outcome of heart attack, stroke and cardiovascular death. SELECT found semaglutide cut these by 20% in people with cardiovascular disease.
Stop rule: NICE's review point for tirzepatide: if weight falls by less than 5% after six months on the highest tolerated dose, decide whether to continue.
QOF: The Quality and Outcomes Framework, the part of the GP contract that pays practices for set work. Tirzepatide prescribing for obesity joined it in April 2026.

This lesson opens on 29 November

The video, the notes, the model answer and the questions open with the full Medicine school on launch day: 93 lessons, with the offer guarantee behind them.

Buy at the early-bird price Watch the free lessons

20 of 36Up next: questionsSkip

The words to use

GLP-1 medicine

A drug that mimics a natural hormone released after eating, helping people feel fuller. Semaglutide (Wegovy) is one; tirzepatide (Mounjaro) also acts on a second hormone.

Funding variation

A NICE arrangement letting the NHS bring in an approved drug in phases, because too many people qualify to treat at once.

Major cardiovascular events

A combined trial outcome of heart attack, stroke and cardiovascular death. SELECT found semaglutide cut these by 20% in people with cardiovascular disease.

Stop rule

NICE's review point for tirzepatide: if weight falls by less than 5% after six months on the highest tolerated dose, decide whether to continue.

QOF

The Quality and Outcomes Framework, the part of the GP contract that pays practices for set work. Tirzepatide prescribing for obesity joined it in April 2026.